# Sherpa Healthcare Partners

> Sherpa Healthcare Partners is a VC fund backing Biotechnology. See 102 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 102
- Last investment: May 2026
- Lead investor: 28%
- Last fund: Jul 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sherpa-capital-%E5%A4%8F%E5%B0%94%E5%B7%B4%E6%8A%95%E8%B5%84
- Website: http://www.sherpahp.com/

Sherpa Healthcare Partners is a VC fund in Beijing focused on Biotechnology and Health Care. Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.

## Contacts

5 contacts available for Sherpa Healthcare Partners. Shizune tracks 8 team members at Sherpa Healthcare Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sherpa-venture-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $7.2M–$50M |
| Series B | $15M–$100M |
| Series C | $12M–$128M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 38 | 37% |
| Health Care | 35 | 34% |
| Medical | 27 | 26% |
| Pharmaceutical | 14 | 14% |
| Biopharma | 10 | 10% |

47 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 33 | 32% |
| Series B | 24 | 24% |
| Series C | 12 | 12% |
| Seed | 8 | 8% |
| Series D | 5 | 5% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 57 | 56% |
| United States | 15 | 15% |
| Kenya | 1 | 1% |
| France | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daqing Cai | founder and Managing partner | 6 | https://shizune.co/investors/profile/cai-daqing |
| Darren Cai | Founder & Managing Partner | 2 | https://shizune.co/investors/profile/darren-cai |
| He Zhu | Vice President | 0 | https://shizune.co/investors/profile/he-zhu |
| Ouyang Xiangyu | Co-Founder & Managing Partner | 0 | https://shizune.co/investors/profile/ouyang-xiangyu-b45d |
| Shi Yina | Managing Director | 1 | https://shizune.co/investors/profile/shi-yina |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ZSPepLib | ZSPepLib is a peptide lead drug developer, established in January 2017, coordinates Zhuzhou, Hunan. It is a platform-based company specializing in peptide lead drug discovery, focusing on the development, production, sales and new peptide drugs of the large-capacity peptide library. Screening R&D technical services. | $44.2M | Series C | May 11, 2026 |  |
| Avisi Technologies | Avisi Technologies develops ophthalmic medical devices using nanotechnology to address vision loss associated with glaucoma and related eye conditions. The company designs implantable solutions such as VisiPlate, an aqueous shunt that regulates intraocular fluid through microchannel structures to help manage eye pressure. Its work combinesmaterials science and ophthalmology to create minimally invasive devices intended for long-term function within the eye. | $10.8M | Series A | Feb 25, 2026 |  |
| Senas Medical | Senas Medical focuses on innovative cardiac electrophysiology solutions. | $14.3M | Series A | Jan 16, 2026 |  |
| Spiro Medical | Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment. The company offers a drug-free approach to controlling severe, chronic airway diseases through its Spiro Neuromodulation System. | $67M | Series A | Jan 07, 2026 |  |
| Huihe Healthcare | Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China. |  | Series D | Dec 27, 2025 |  |
| Link Cell Therapies | Link Cell Therapies develops engineered cell therapy technologies intended to create targeted CAR T-based treatments for cancer. The company applies proprietary logic-gating methods that require co-expression of multiple cancer antigens to activate therapeutic T cells, aiming to focus immune cell activity on tumor cells while reducing effects onnon-cancerous tissues. Its work spans programs for solid tumors and certain hematologic cancers, with lead candidates progressing through preclinical development and preparation for clinical research. Link Cell Therapies also explores additional platforms and therapeutic programs that build on its core targeting technology to expand applications of engineered cellular therapies. | $60M | Series A | Dec 15, 2025 |  |
| Starna Therapeutics | Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields. | $42.1M | Series B | Oct 24, 2025 |  |
| AusperBio | AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $63M | Series B | Sep 21, 2025 |  |
| AusperBio | AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $50.3M | Series B | May 28, 2025 |  |
| PAQ Therapeutics | PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring health and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation. | $39M | Series B | May 05, 2025 |  |

10 of 102 investments shown.

## Co-investors
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 13 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 13 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 11 deals together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 10 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 7 deals together
- [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-capital) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Health Care Investors in Asia](https://shizune.co/investors/health-care-investors-asia)
- [Health Care VC Funds in Asia](https://shizune.co/investors/health-care-vc-funds-asia)
- [Health Care Investors in China](https://shizune.co/investors/health-care-investors-china)
- [Health Care VC Funds in China](https://shizune.co/investors/health-care-vc-funds-china)
- [Biotechnology Investors in Asia](https://shizune.co/investors/biotechnology-investors-asia)
- [Biotechnology VC Funds in Asia](https://shizune.co/investors/biotechnology-vc-funds-asia)

## FAQ

### What does Sherpa Healthcare Partners invest in?

Sherpa Healthcare Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 102 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sherpa Healthcare Partners's check size?

Sherpa Healthcare Partners typically joins rounds of $7.2M–$50M at Series A, $15M–$100M at Series B and $12M–$128M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sherpa Healthcare Partners participates in.

### How do I contact Sherpa Healthcare Partners?

Public channels for Sherpa Healthcare Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sherpa Healthcare Partners?

The team at Sherpa Healthcare Partners includes Daqing Cai (founder and Managing partner), Darren Cai (Founder & Managing Partner) and He Zhu (Vice President), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co